David Moatazedi Sells 6,251 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,251 shares of the stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares of the company’s stock, valued at $6,306,875.60. This trade represents a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Evolus Trading Down 1.6 %

NASDAQ:EOLS traded down $0.19 during mid-day trading on Friday, hitting $12.05. 733,234 shares of the company’s stock were exchanged, compared to its average volume of 619,683. Evolus, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $766.22 million, a P/E ratio of -13.24 and a beta of 1.28. The company has a 50 day simple moving average of $13.63 and a 200-day simple moving average of $13.82.

Institutional Trading of Evolus

Institutional investors have recently modified their holdings of the business. Tri Locum Partners LP acquired a new position in shares of Evolus in the fourth quarter worth approximately $8,198,000. Gilder Gagnon Howe & Co. LLC raised its stake in Evolus by 287.2% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock worth $7,753,000 after buying an additional 520,859 shares during the last quarter. Caligan Partners LP lifted its holdings in Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after buying an additional 498,900 shares during the period. Allostery Investments LP bought a new stake in Evolus during the fourth quarter valued at $4,760,000. Finally, Altium Capital Management LLC boosted its position in Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock valued at $7,562,000 after acquiring an additional 330,000 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on EOLS shares. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays increased their price target on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.